Navigation Links
Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
Date:10/31/2007

CRANBURY, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) announced today the initiation of dosing in a Phase 1 clinical trial of PL-3994, a long acting analog of atrial natriuretic peptide, under development for treatment of acute decompensated congestive heart failure (CHF). The trial is being conducted under an Investigational New Drug application Palatin submitted to the U.S. Food and Drug Administration. Future plans include the development of PL-3994 for long term administration in patients with chronic congestive heart failure.

The Phase 1 trial of PL-3994 is a randomized, double-blind, placebo- controlled, single-ascending dose study in healthy volunteers who will receive the drug subcutaneously. The evaluations will include safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including endogenous messenger levels such as cyclic guanosine monophosphate.

Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development, stated, "We are excited to begin clinical trials of PL-3994, a compound developed by Palatin scientists that has the potential to become a new tool for physicians to advance the treatment of congestive heart failure. CHF is the single most common cause of hospitalization in the U.S. for patients older than 65 years of age and an underserved medical condition."

Atrial natriuretic peptide (ANP) is a naturally produced peptide hormone involved in regulation of water and sodium levels in the circulation. Palatin's PL-3994 is a peptidomimetic compound, which incorporates features of both natural ANP and small molecules.

Preclinical studies have demonstrated that PL-3994 is highly potent. Its longer duratio
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
3. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Cardiologists at Henry Ford ... stroke in patients with an irregular heartbeat. With ... Henry Ford is able to add another option ... fibrillation, which affects the heart,s ability to pump. ... and first-ever commercial Watchman implant at a non-clinical trial ...
(Date:4/21/2015)... -- According to a new market ... Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), ... Contamination, Adventitious Agents) - Global Forecast to 2019", ... Market was valued at $1,758.69 Million in 2014. ... CAGR of 12.23% to reach $3,130.85 Million in ...
(Date:4/21/2015)... -- Seattle Children,s announced today that 20 of 22 ... genetically reprogrammed T cells to treat relapsed acute lymphoblastic ... sensitive tests designed to detect minute amounts of cancer ... included children with very high tumor burdens as well ... "These results are extremely encouraging," said ...
Breaking Medicine Technology:Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 3
(Date:4/21/2015)... 2015 Carinsurancehints.com has released a new ... their impact on auto insurance prices . ... insurance prices. Clients should review their insurance options before ... bought under several forms. Some of the popular policies ... can compare online rates and find the best prices ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery sponsored ... world famous Avalon Hollywood. Organized by Debbie Durkin, Los ... and film, the EcoLuxe Lounge is a premier red ... and festivals throughout the year. A gathering of some ... conscious products and services, this daylong event is attended ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4
... ... be a profitable 2010, the new Wella SP range is set to raise the ... ... hair company in the world, Wella is at the forefront of hairdressing innovation. The introduction ...
... ... struggle to find the balance between investing in the necessary internal resources to implement ... for a dozen online tactics, and identifies where companies are using each tactic in ... ...
... ... of the most common negative patterns in a relationship. Angry individuals may be aware of ... Path.com. , ... (PRWEB) February 1, 2010 -- Personal Power Path announces the launch of an anger management ...
... , Feb. 1 /PRNewswire / -- Ervin Cohen ... announced today that David Bricker , Of Counsel to ... clients last Friday, January 29, 2010 , in a medical malpractice ... Hopp of the Riverside Superior Court and a jury panel of 12. ...
... , BIRMINGHAM, Ala. , Feb. 1 ... Jon P. Stonehouse , President and Chief Executive Officer of BioCryst, plans ... forodesine and BCX4208 at the 12 th Annual BIO CEO ... at 10:30 a.m. Eastern Time . , Links to a ...
... contrast agent gadolinium during magnetic resonance imaging (MRI) for ... metastases, according to a new study published online February ... Institute . Gadolinium-enhanced MRI is primarily used to visualize ... and evaluate lymph node metastases. In light of this ...
Cached Medicine News:Health News:ckwrites.com Releases Report On Creating Online Marketing Tactics 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 2Health News:Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict 3Health News:BioCryst To Present At 12th Annual BIO CEO & Investor Conference 2Health News:News brief: Contrast agent with MRI improves detection of lymph nodes metastases 2
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
... Operating as a constant voltage power supply, the ... knob and hilo range switch control the output, ... to 250 volts. One, two-position switch toggles the ... output current. The 105 is equipped with an ...
... The 250-90 low voltage electrophoresis power supply ... 500 milliamps and 125 watts. This product operates ... continuously variable output. The 250-90 automatically crosses over ... when a preset limit is reached. ...
Medicine Products: